CD19-CAR-T cells

BIOLOGICAL2 trials

Sponsors

Bioceltech Therapeutics, Ltd., Hebei Yanda Ludaopei Hospital

Conditions

B-cell Acute Lymphoblastic LeukemiaB-cell Malignancy

Phase 1

CD19-CAR-T Cells in Patients With R/R B-ALL

Bioceltech Therapeutics, Ltd.B-cell Acute Lymphoblastic Leukemia

Start: 2018-07-20End: 2019-12-31Target: 40Updated: 2018-06-29

CD19-CAR-T in B-cell Malignancies Patients

CompletedNCT03952923

Hebei Yanda Ludaopei HospitalB-cell Malignancy

Start: 2019-08-01End: 2021-03-31Updated: 2022-02-01

Related Papers

Significant Long-Term Benefits of CAR T-Cell Therapy Followed By a Second Allo-HSCT for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Who Relapsed after an Initial Transplant

Blood2020-11-042 citations